GENE ONLINE|News &
Opinion
Blog

2021-10-14| Special

Apnimed’s Oral Drug for Obstructive Sleep Apnea Registers Encouraging Outcomes in Two Phase 2 Trials

by Rajaneesh K. Gopinath
Share To
Sleep apnea is a serious disorder characterized by repeated breathing interruptions during sleep. Among the many types of sleep apnea, obstructive Sleep Apnea (OSA) is the most common, affecting 17% of women and 34% of men in the US. The disorder is often underdiagnosed and is estimated to affect more than 25 million Americans.

OSA occurs when throat muscles intermittently relax after sleep and cause partial or complete upper airway closure. As a result, blood oxygen levels get lowered, and the brain briefly wakes patients from their slumber. This often leads to poor sleep and aggravates other medical conditions such as hypertension, diabetes, cardiovascular disease, and stroke. Besides, impaired sleep also affects work productivity, reduces functional ability, and lowers the quality of life.

Cambridge, MA-based Apnimed is a clinical-stage company that aims to develop novel therapies for sleep apnea and related disorders. On October 13th, the company announced top-line results from two Phase 2 trials, APC-003 and APC-004, evaluating AD109, its investigational, oral medicine for patients with OSA.

GO Prime with only $1.49 now

LATEST
The Golden Age of Medicine: Advancements in Novel Modalities and Therapeutic Areas
2024-11-01
Strengthening Biotech Ties: Highlights from the BioConnect Forum and Future Collaboration between Taiwan and Australia
2024-10-31
AusBiotech 2024 Opening Ceremony: From Local to Global – Shaping the Future of Life Sciences and Biotech in Australia
2024-10-30
AMS BioteQ Showcases Game-Changing Innovations at Medical Japan 2024
2024-10-29
AusBiotech 2024 to Highlight Global Areas of Interest, Current Trends, and Research Directives in Australia’s Diverse Biotech Industry
2024-10-25
BPIPO and DCB Collaborate with NVIDIA to Host AI Forum, Focusing on Cross-Domain Integration for Precision Health
2024-10-25
CDMO Samsung Bio Secures Record $1.24 Billion Biopharma Manufacturing Contract, Raising Total 2024 Deal Value to Over $3.3 Billion
2024-10-23
EVENT
2024-11-04
BIO-Europe 2024
Stockholm, Sweden
Scroll to Top